PT-141 Nasal Spray (10mg)
Technické špecifikácie
| Čistota (HPLC) | ≥99% (HPLC) |
| CAS číslo | 189691-06-3 |
| Forma | White lyophilized powder |
| Skladovanie | -20°C |
| Sekvencia | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Molekulová hmotnosť | 1,025.21 g/mol |
| Soľná forma | Acetate |
| Rozpustnosť | Soluble in water |
PT-141 Nasal Spray (10mg)
Katalógová cena v EUR · HU, SK, CZ, PL
- Eurozone (EUR)243,00 EUR
- Maďarsko (HU)243,00 EUR≈ 97 200 Ft
- Slovensko (SK)243,00 EUR
- Česko (CZ)243,00 EUR≈ 6 075 Kč
- Poľsko (PL)243,00 EUR≈ 1032,75 zł
Rovnaká katalógová cena v EUR pri doručení do Maďarska, Slovenska, Česka a Poľska. Platba v EUR.
Orientačné HUF/CZK/PLN prepočítané z EUR; Slovensko používa EUR. Kurzy približné. Platba v EUR.
Bremelanotide (PT-141) pre-formulated as a nasal spray for libido and melanocortin research. 10mg total.
Len na laboratórny výskum.
Nie je určené na ľudskú spotrebu, veterinárne ani diagnostické použitie.
From the Peptide Explorer
A cyclic heptapeptide melanocortin receptor agonist (primarily MC4R) developed from the Melanotan II scaffold. Unlike phosphodiesterase inhibitors, PT-141 acts centrally through hypothalamic melanocortin pathways, representing a mechanistically distinct approach to sexual function research.
Key Mechanisms
- ›MC4R agonism (central, hypothalamic)
- ›MC3R partial agonism
- ›CNS-mediated arousal pathway
- ›Dopaminergic downstream signaling
- ›Independent of vascular mechanisms
Primary Research Areas
- ›Hypoactive sexual desire
- ›Melanocortin receptor pharmacology
- ›Central arousal pathways
- ›Female sexual dysfunction
Key Research Findings
- FDA-approved (as Vyleesi) for premenopausal HSDD (2019)
- Acts via central MC4R pathway, distinct from PDE5 inhibitors
- Demonstrated efficacy in both male and female models of sexual dysfunction
Research Overview
A cyclic heptapeptide melanocortin receptor agonist (primarily MC4R) developed from the Melanotan II scaffold. Unlike phosphodiesterase inhibitors, PT-141 acts centrally through hypothalamic melanocortin pathways, representing a mechanistically distinct approach to sexual function research.
Origin: Derived from Melanotan II; developed by Palatin Technologies
Mechanism of Action
- MC4R agonism (central, hypothalamic)
- MC3R partial agonism
- CNS-mediated arousal pathway
- Dopaminergic downstream signaling
- Independent of vascular mechanisms
Primary Research Areas
- Hypoactive sexual desire
- Melanocortin receptor pharmacology
- Central arousal pathways
- Female sexual dysfunction
Key Published Findings
- FDA-approved (as Vyleesi) for premenopausal HSDD (2019)
- Acts via central MC4R pathway, distinct from PDE5 inhibitors
- Demonstrated efficacy in both male and female models of sexual dysfunction
Research Protocol
Commonly studied routes: Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.
Storage
-20°C lyophilized, 2-8°C reconstituted
Important Notice
PT-141 Nasal Spray (10mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.
Výskumné špecifikácie
Synthesized for strict analytical consistency. Verified via HPLC/MS.Zobraziť štandardy kvality →
Manipulácia a skladovanie
- Store lyophilized at -20°C
- Protect from light and moisture
- Use sterile bacteriostatic water for reconstitution
- Minimize freeze-thaw cycles
- Solubility: Soluble in water